Skip to main content
RENERVE LIMITED logo

RENERVE LIMITED — Investor Relations & Filings

Ticker · RNV ISIN · AU0000358616 ASX Manufacturing
Open in API
Filings indexed 134 across all filing types
Latest filing 2025-11-19 Capital/Financing Update
Country AU Australia
Listing ASX RNV

About RENERVE LIMITED

https://renerve.com.au/

Renerve Limited is a medical technology company focused on the development and commercialization of advanced solutions for tissue repair and regeneration. The company specializes in peripheral nerve repair through its proprietary NervAlign platform. This technology utilizes a specialized decellularization process to create high-quality nerve grafts derived from porcine tissue. These grafts are designed to provide a natural scaffold that supports and guides axonal regrowth across nerve gaps, offering an alternative to traditional autografts. By maintaining the structural integrity and biochemical cues of the extracellular matrix, Renerve's products aim to improve functional recovery outcomes for patients suffering from traumatic nerve injuries. The company's research and development efforts are centered on expanding the applications of its tissue engineering platform to address various clinical needs in regenerative medicine.

Recent filings

Filing Released Lang Actions
Proposed issue of securities - RNV 5 pages 18.6KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B - Proposed issue of securities' and details a proposed issue of new securities (options) by RENERVE LIMITED. It includes specifics about the number of securities, issue date, conditions such as shareholder approval, and the purpose of the issue (consideration for acting as joint lead manager for a capital raising via placement). The document is a formal announcement to the ASX regarding a capital raising activity and issuance of new securities. It does not contain financial statements or detailed financial performance data, nor is it a report or transcript. It is clearly an update on financing activities and capital structure changes. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length (6591 characters) supports it being a full announcement rather than a brief notice or report publication announcement.
2025-11-19 English
Trading Halt 2 pages 262.4KB
Capital/Financing Update Classification · 95% confidence The document is a market announcement from ReNerve Limited regarding a trading halt requested by the company. The text explicitly states that the trading halt is requested in connection with a proposed equity raising by way of a share placement. There is no financial data, report, or detailed analysis present. The document is short (1998 characters) and serves as an announcement of a trading halt related to capital raising activities. According to the filing definitions, updates on company fundraising or capital structure changes fall under Capital/Financing Update (CAP). Therefore, this document is best classified as a Capital/Financing Update (CAP).
2025-11-17 English
Nerve Cuff approved for use in US DoD and VA hospitals 3 pages 236.0KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 13 November 2025 from ReNerve Limited. It announces the approval of the company's NervAlign® Nerve Cuff for use in the US Department of Defense and Veterans Affairs healthcare systems, along with initial and repeat purchase orders. The content focuses on product approval, market traction, and company growth, without any financial statements, detailed financial performance data, or regulatory filing references. The document is a corporate announcement about a product approval and sales update rather than a financial report or regulatory filing. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Capital Update. It is not a report publication announcement since it contains substantive information rather than just announcing a report release. The best fitting category is Regulatory Filings (RNS), which serves as a general category for regulatory announcements and company news that do not fit other specific categories.
2025-11-12 English
Quarterly Investor Presentation 21 pages 2.9MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation by ReNerve Ltd, covering product portfolios, market opportunities, sales and marketing updates, clinical study results, and forward-looking statements. It includes extensive information about the company's products, market expansion, sales channels, and clinical validation. The document is structured as a presentation with slides, images, and detailed business and product information. It is not a formal financial report, audit, earnings release, or regulatory filing. It is also not a transcript of a call or a legal proceeding. The content is typical of an investor presentation aimed at providing investors and stakeholders with an overview of the company's strategy, products, market position, and growth prospects. Therefore, the most appropriate classification is Investor Presentation (IP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2025-11-09 English
Quarterly Investor Webinar 2 pages 235.0KB
Investor Presentation Classification · 90% confidence The document is an ASX announcement dated 5 November 2025 inviting shareholders and investors to a webinar discussing the September 2025 quarterly report and recent company developments. It does not contain the quarterly report itself or substantive financial data, but rather is an invitation to a presentation about the quarterly report. The document length is 4367 characters, which is relatively short and consistent with an announcement rather than a full report. The content focuses on the webinar details, company background, and product information, without detailed financial statements or analysis. Therefore, this document is best classified as an Investor Presentation (IP) announcement rather than the actual quarterly report (IR) or earnings release (ER).
2025-11-04 English
ReNerve Clinical Study Expansion 3 pages 323.3KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 5 November 2025 from ReNerve Limited about the expansion of a clinical study evaluating the NervAlign Nerve Cuff. It discusses clinical trial details, interim data, product portfolio, market growth, and company vision. There are no financial statements, earnings data, or regulatory filings such as 10-K or interim reports. The document is a corporate announcement focused on clinical study progress and product development, not a financial report or regulatory filing. It is not a report publication announcement since it contains substantive information rather than just announcing a report release. The content fits best under a general regulatory announcement category for corporate news that does not fit other specific categories. Therefore, the appropriate classification is Regulatory Filings (RNS).
2025-11-04 English

Browse filings by year

3 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.